Steven Cohen Cogent Biosciences, Inc. Transaction History
Point72 Asset Management, L.P.
- $44.6 Billion
- Q2 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 4,911,924 shares of COGT stock, worth $73.5 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
4,911,924
Previous 5,295,545
7.24%
Holding current value
$73.5 Million
Previous $31.7 Million
11.18%
% of portfolio
0.08%
Previous 0.08%
Shares
18 transactions
Others Institutions Holding COGT
# of Institutions
203Shares Held
117MCall Options Held
2.84MPut Options Held
828K-
Paradigm Biocapital Advisors LP New York, NY10.4MShares$155 Million3.47% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.49MShares$127 Million7.28% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$109 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$104 Million10.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.52MShares$97.6 Million0.0% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $984M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...